Simon Delmotte 
The result of 20 years of basic and clinical research, Hemerion continues to develop new therapeutic approaches to improve cancer treatment.Since 2020, our R&D team has been building ambitious partnerships with several key players in public and private research.The collaboration with Lesaffre is part of this drive to accelerate our research through contact with other …
Hemerion Therapeutics will take stage at this year’s Society of Neuro-Oncology (SNO) Annual Congress, held from November 21 to 24, 2024, in Houston. This prestigious event, known for bringing together the world’s top researchers, clinicians, and industry experts in the field of brain cancer research, is an ideal platform for Hemerion to present its pioneering …
In July 2024, Hemerion launched a participatory investment campaign in partnership with the Capital Cell platform. To answer investors’ questions, two webinars open to the public were organized in September 2024. At the end of September, Hemerion organized two webinars dedicated to its participative investment campaign organized with Capital Cell. The aim of these webinars …
In addition to a new financing round organized to prepare for the pivotal phases of clinical development of its Pentalafen / Heliance therapy, Hemerion is launching a crowdfunding campaign on the Capital Cell platform. Launch date: July 15, 2024, with the objective of raising €1.2 million. Since its founding in 2020, Hemerion has raised over …
The Pentalafen®/Heliance® combination therapy developed by Hemerion is designed to enhance the treatment of glioblastoma, the most prevalent brain cancer. This solution has already reached a significant level of clinical advancement and has recently been awarded a grant under the France 2030 investment plan, which will support its transition to the industrial and commercial phase. …
The Pentalafen® / Heliance® combination therapy developed by Hemerion is based on a technology tested in a phase 1 clinical trial sponsored by the University Hospital of Lille (INDYGO) between 2017 and 2021 in the treatment of glioblastoma. The results of the long-term follow-up of this clinical trial were published in the May 16, 2024 …
A first patient was treated in Pittsburgh, Pennsylvania in the United States in early April 2024 as part of the new clinical trial sponsored by Hemerion.This study (HTX-GBM-01) is designed to confirm the safety and feasibility of the Pentalafen® / Heliance® combination therapy in the treatment of glioblastoma, the most common and aggressive form of …
Costas G. Hadjipanayis, MD, PhD, L. Dade Lunsford Professor at the University of Pittsburgh and director of the UPMC Center for Image-Guided Neurosurgery, has been elected as the new chair of the Section on Tumors of the AANS/CNS (American Association of Neurosurgeons / Congress of Neurosurgeons). This will put him at the forefront of the …
Hemerion recently completed the final preparations for the start of its next clinical trial in the US. Set-up, verification of equipment and procedures, training of a first neurosurgery team: Hemerion led a 3-day mission to the University of Pittsburgh’s Presbyterian Hospital to prepare to treat the first patients. In early April 2024, Hemerion initiated a …
Hemerion a récemment finalisé les derniers préparatifs pour le lancement de son prochain essai clinique au USA. Mise en place, vérification des équipements et des procédures, formation des équipes de neurochirurgie : Hemerion a mené une mission de 3 jours au Presbyterian Hospital de l’Université de Pittsburgh pour préparer les traitements des premiers patients. Hemerion …